Randomized Clinical Trials in Pancreatic Cancer

Neha Goel; Sanjay S Reddy

doi:10.1016/j.soc.2017.05.005

Randomized Clinical Trials in Pancreatic Cancer

Surg Oncol Clin N Am. 2017 Oct;26(4):767-790. doi: 10.1016/j.soc.2017.05.005. Epub 2017 Aug 4.

Authors

Neha Goel¹, Sanjay S Reddy²

Affiliations

¹ Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA.
² Department of Surgical Oncology, Fox Chase Cancer Center, 333 Cottman Avenue, Philadelphia, PA 19111, USA. Electronic address: sanjay.reddy@fccc.edu.

PMID: 28923230
DOI: 10.1016/j.soc.2017.05.005

Abstract

The management of pancreatic cancer has grown rapidly in the last decade. The Gastrointestinal Tumor Study Group trial in 1985 supported postoperative chemoradiation, and a more recent study recommended 6 months of adjuvant gemcitabine and capecitabine or monotherapy with gemcitabine or fluorouracil plus folinic acid, in the absence of neoadjuvant therapy. Clinicians are now studying the role of targeted therapy in pancreatic cancer and neoadjuvant chemotherapy in resectable, borderline resectable, and locally advanced pancreatic cancer. This article critically evaluates the evolution of pancreatic cancer management, focussing on level 1a, prospective randomized control trials from 2007 to 2017.

Keywords: Chemoradiation; Chemotherapy; Pancreatic cancer; Randomized control trails; Randomized trials.

Publication types

Review

MeSH terms

Antineoplastic Combined Chemotherapy Protocols*
Chemotherapy, Adjuvant / methods*
Fluorouracil / therapeutic use
Humans
Neoadjuvant Therapy
Pancreatic Neoplasms / diagnosis
Pancreatic Neoplasms / therapy*
Prospective Studies
Randomized Controlled Trials as Topic*

Substances

Fluorouracil